This was assessed in a retrospective study in which stage IV NSCLC MET exon 14 skipping patients with >50% PD-L1 expression treated as first-line therapy with Pembrolizumab showed an improved therapeutic outcome [95]. Here, CD274 is linked to non-small cell lung carcinoma.